Hôpital Cochin, Service de gastroentérologie et d’oncologie digestive, 27 rue du Faubourg Saint Jacques, 75014 Paris
Unité INSERM U1016, Faculté de médecine, Université de Paris, Paris
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity in somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE. These radio markers have been used for several years in the treatment of advanced neuroendocrine tumours. Recently, the randomized Phase III study NETTER-1 compared 177Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favour of efficiency seem to exist in the other neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications and the safety of the therapy.
This work is licensed under a
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License